Tags

Type your tag names separated by a space and hit enter

Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism.
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 01; 34(1):32-6.PN

Abstract

BACKGROUND

There are several lines of evidence to indicate that the immune system plays an important role in the pathophysiology of autism. The objective of this study was to access the effects of pentoxifylline plus risperidone in the treatment of autistic disorder.

METHODS

Forty children between the ages 4 and 12 years with a DSM IV-TR clinical diagnosis of autism were recruited. The children presented with a chief complaint of severely disruptive symptoms related to autistic disorder. Patients were randomly allocated to pentoxifylline+risperidone or placebo+risperidone for a 10-week, double-blind, placebo-controlled study. The dose of risperidone was titrated up to 3 mg/day, pentoxifylline was titrated to 600 mg/day. Patients were assessed at baseline and after 2, 4, 6, 8 and 10 weeks of starting medication. The measure of the outcome was the Aberrant Behavior Checklist-Community (ABC-C).

RESULTS

The difference between the two protocols was significant as the group that received pentoxifylline had greater reduction in ABC-C subscale scores for Irritability, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/Noncompliance and Inappropriate Speech.

CONCLUSION

The results suggest that combination of atypical antipsychotic medications and pentoxifylline might have synergistic effects in treatment of behavioral problems of children with autism.

Authors+Show Affiliations

Psychiatric Research Centre, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran 13337, Iran. s.akhond@neda.netNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19772883

Citation

Akhondzadeh, Shahin, et al. "Double-blind Placebo-controlled Trial of Pentoxifylline Added to Risperidone: Effects On Aberrant Behavior in Children With Autism." Progress in Neuro-psychopharmacology & Biological Psychiatry, vol. 34, no. 1, 2010, pp. 32-6.
Akhondzadeh S, Fallah J, Mohammadi MR, et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(1):32-6.
Akhondzadeh, S., Fallah, J., Mohammadi, M. R., Imani, R., Mohammadi, M., Salehi, B., Ghanizadeh, A., Raznahan, M., Mohebbi-Rasa, S., Rezazadeh, S. A., & Forghani, S. (2010). Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Progress in Neuro-psychopharmacology & Biological Psychiatry, 34(1), 32-6. https://doi.org/10.1016/j.pnpbp.2009.09.012
Akhondzadeh S, et al. Double-blind Placebo-controlled Trial of Pentoxifylline Added to Risperidone: Effects On Aberrant Behavior in Children With Autism. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1;34(1):32-6. PubMed PMID: 19772883.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. AU - Akhondzadeh,Shahin, AU - Fallah,Jalil, AU - Mohammadi,Mohammad-Reza, AU - Imani,Reza, AU - Mohammadi,Mohammad, AU - Salehi,Bahman, AU - Ghanizadeh,Ahmad, AU - Raznahan,Maedeh, AU - Mohebbi-Rasa,Soodeh, AU - Rezazadeh,Shams-Ali, AU - Forghani,Saeedeh, Y1 - 2009/09/20/ PY - 2009/06/27/received PY - 2009/09/12/revised PY - 2009/09/12/accepted PY - 2009/9/24/entrez PY - 2009/9/24/pubmed PY - 2010/4/8/medline SP - 32 EP - 6 JF - Progress in neuro-psychopharmacology & biological psychiatry JO - Prog Neuropsychopharmacol Biol Psychiatry VL - 34 IS - 1 N2 - BACKGROUND: There are several lines of evidence to indicate that the immune system plays an important role in the pathophysiology of autism. The objective of this study was to access the effects of pentoxifylline plus risperidone in the treatment of autistic disorder. METHODS: Forty children between the ages 4 and 12 years with a DSM IV-TR clinical diagnosis of autism were recruited. The children presented with a chief complaint of severely disruptive symptoms related to autistic disorder. Patients were randomly allocated to pentoxifylline+risperidone or placebo+risperidone for a 10-week, double-blind, placebo-controlled study. The dose of risperidone was titrated up to 3 mg/day, pentoxifylline was titrated to 600 mg/day. Patients were assessed at baseline and after 2, 4, 6, 8 and 10 weeks of starting medication. The measure of the outcome was the Aberrant Behavior Checklist-Community (ABC-C). RESULTS: The difference between the two protocols was significant as the group that received pentoxifylline had greater reduction in ABC-C subscale scores for Irritability, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/Noncompliance and Inappropriate Speech. CONCLUSION: The results suggest that combination of atypical antipsychotic medications and pentoxifylline might have synergistic effects in treatment of behavioral problems of children with autism. SN - 1878-4216 UR - https://www.unboundmedicine.com/medline/citation/19772883/Double_blind_placebo_controlled_trial_of_pentoxifylline_added_to_risperidone:_effects_on_aberrant_behavior_in_children_with_autism_ DB - PRIME DP - Unbound Medicine ER -